SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-002307
Filing Date
2023-11-09
Accepted
2023-11-09 16:31:53
Documents
66
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrkr-20230930x10q.htm   iXBRL 10-Q 1406503
2 EX-31.1 mrkr-20230930xex31d1.htm EX-31.1 14764
3 EX-31.2 mrkr-20230930xex31d2.htm EX-31.2 14777
4 EX-32.1 mrkr-20230930xex32d1.htm EX-32.1 6571
5 EX-32.2 mrkr-20230930xex32d2.htm EX-32.2 6590
6 GRAPHIC mrkr-20230930x10q001.jpg GRAPHIC 12637
7 GRAPHIC mrkr-20230930x10q004.jpg GRAPHIC 79198
  Complete submission text file 0001410578-23-002307.txt   6212659

Data Files

Seq Description Document Type Size
8 EX-101.SCH mrkr-20230930.xsd EX-101.SCH 42744
9 EX-101.CAL mrkr-20230930_cal.xml EX-101.CAL 41732
10 EX-101.DEF mrkr-20230930_def.xml EX-101.DEF 190736
11 EX-101.LAB mrkr-20230930_lab.xml EX-101.LAB 360792
12 EX-101.PRE mrkr-20230930_pre.xml EX-101.PRE 290250
60 EXTRACTED XBRL INSTANCE DOCUMENT mrkr-20230930x10q_htm.xml XML 987265
Mailing Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032
Business Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37939 | Film No.: 231393127
SIC: 2834 Pharmaceutical Preparations